Bisphosphonates in oncology: Evidence for the prevention of skeletal events in patients with bone metastases

Drug Design, Development and Therapy

Volumn , Issue 3, 2009, Pages 27-40

  Polascik, Thomas J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Bone metastases; Cancer; Prevention; Skeletal related events

Indexed keywords

CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LUNG CANCER; MULTIPLE MYELOMA; NEPHROTOXICITY; PROSTATE CANCER; REVIEW; SKELETAL RELATED EVENT;

EID: 77953658367     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010-2018.
2. Hodgson SF, Watts NB; for AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Prac. 2003;9(6):544-564.
3. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(suppl 4):14-27.
4. Actonel [package insert]. Cincinnati, OH: Proctor and Gamble Pharmaceuticals, Incorporated; 2008.
5. Actonel plus calcium [package insert]. Cincinnati, OH: Proctor & Gamble Pharmaceuticals, Incorporated; 2008.
6. Boniva Injection [package insert]. Nutley, NJ; Roche Pharmaceuticals; 2006.
7. Boniva Tablets [package insert]. Nutley, NJ; Roche Pharmaceuticals; 2006.
8. Fosamax [package insert]. Whitehouse Station, NJ; Merck & Co; 2008.
9. Fosamax plus D [package insert]. Whitehouse Station, NJ; Merck & Co; 2008.
10. Reclast [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; 2008.
11. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. (Pubitemid 46698462)
12. Lyles KW, Colón-Emeric CS, Magaziner JS, et al; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357(18);1799-1809.
13. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-567. (Pubitemid 32112871)
14. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther. 2007;4(2):92-100. (Pubitemid 46396665)
15. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420-432.
16. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004;67(5-6):390-396.
17. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-6249s.
18. Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80(8):1546-1556.
19. Coleman R, Brown J, Terpos E, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008;34(7):629-639.
20. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20 Pt 2):6213s-6216s. (Pubitemid 44703792)
21. Berenson JR, Rajdev L, Broder M. Treatment strategies for skeletal complications of cancer. Cancer Biol Ther. 2006;5(9):1074-1077. (Pubitemid 44772213)
22. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119:S150-S162.
23. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther. 2006;28(2):151-173.
24. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12(20, pt 2):6222s-6230s. (Pubitemid 44703794)
25. Zometa [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; 2008.
26. Aredia [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; 2007.
27. European public assessment report: bondronat. European Medicines Agency Web site. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/ bondronat/bondronat.htm. Accessed August 17, 2008.
28. European public assessment report: zometa. European Medicines Agency Web site. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/zometa/ zometa.htm. Accessed August 16, 2008.
29. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21(7):1404-1411. (Pubitemid 46606423)
30. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.
31. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744. (Pubitemid 37238631)
32. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36-43. (Pubitemid 37553537)
33. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321. (Pubitemid 46243475)
34. Carteni G, Bordonaro R, Giotta F, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist. 2006;11(7):841-848. (Pubitemid 44157572)
35. Hortobagyi GN, Theriault RL, Porter L, et al; for the Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335(24):1785-1791.
36. Hortobagyi GN, Theriault RL, Porter L, et al; for the Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. J Clin Oncol. 1998;16(6):2038-2044.
37. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17(3):846-854.
38. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082-1090. (Pubitemid 30127670)
39. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405.
40. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133-1137.
41. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59-65. (Pubitemid 23059975)
42. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246(1):67-74. (Pubitemid 29327354)
43. Saad F, Gleason DM, Murray R, et al; for Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
44. Saad F, Gleason DM, Murray R, et al; for Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-882. (Pubitemid 39429674)
45. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277-4284. (Pubitemid 46621802)
46. Dearnaley DP, Sydes MR, Mason MD, et al; for the MRC PR05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95(17):1300-1311.
47. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-3157. (Pubitemid 46606297)
48. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613-2621. (Pubitemid 38715767)
49. Heras P, Karagiannis S, Kritikos K, Hatzopoulos A, Mitsibounas D. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care. 2007;16(6):539-542.
50. Piga A, Bracci R, Ferretti B, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res. 1998;17(2):213-217. (Pubitemid 28335581)
51. Berenson JR, Lichtenstein A, Porter L, et al; for Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334(8):488-493.
52. Berenson JR, Lichtenstein A, Porter L, et al; for the Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16(2):593-602.
53. Menssen HD, Sakalová A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20(9):2353-2359. (Pubitemid 34441663)
54. McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1996;100(2):317-325.
55. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 2001;113(4):1035-1043.
56. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-567. (Pubitemid 32112871)
57. Hilner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-4057.
58. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 2.2008). © 2008 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed July 14, 2008.
59. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;20(3):CD003474.
60. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 1.2008). © 2008 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed July 14, 2008.
61. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006;4:CD006250.
62. Hoosier Oncology Group. Phase III, randomized, double-blind, placebo-controlled trial evaluating the ability of risedronate to prevent skeletal related events in patients with metastatic prostate cancer commencing hormonal therapy: Hoosier Oncology Group GU02-41. ClinicalTrials. gov. http://www.clinicaltrials.gov/ct2/show/NCT00216060?term= risedronate+prostate&rank=2. Accessed July 15, 2008.
63. Zoledronate in preventing skeletal (bone)-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/ NCT00698308?term=NCT00698308&rank=1. Accessed July 15, 2008.
64. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 1.2009). © 2009 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed October 1, 2008.
65. Zoledronic acid treatment (every 4 or 12 weeks) to prevent skeletal complications in advanced multiple myeloma patients (Z-MARK). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00622505?term= zoledronic+acid+multiple+myeloma&rank=4. Accessed August 16, 2008.
66. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464-2472.
67. Clemons M, Dranitsaris G, Cole D, Gainford MC. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist. 2006;11(3):227-233.
68. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59-69.
69. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998;34(13):2021-2026. (Pubitemid 28546935)
70. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov. Accessed October 14, 2008.